



Pfizer Completes Acquisition of Baxter's Marketed Vaccines

Monday, December 01, 2014 - 02:30am

Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of Baxter International Inc.'s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. As previously announced, Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where these vaccines are manufactured.

"NeisVac-C and FSME-IMMUN/Ticovac are a strong fit with our vaccines business and this acquisition adds value, scale and depth to our existing portfolio of innovative vaccines," said Susan Silbermann, president and general manager, Pfizer Vaccines. "These best-in-class products enable us to reach a broader population with vaccines that prevent infections from serious and often fatal diseases."

About NeisVac-C and FSME-IMMUN/Ticovac

NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococci (MenC). This serious infection of the membrane covering the brain may be fatal in roughly 10-15 percent of patients¹ and 30 percent to more than 50 percent of survivors may suffer from severe physical, social and mental damage². MenC is one of the most prevalent meningococcal serogroups in many parts of the world and vaccination with NeisVac-C has been shown to be highly effective.

FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis (TBE), an infection of the brain, which is transmitted by the bite of ticks infected with the TBE-virus. Every year, the TBE virus causes thousands of cases of neuroinvasive illness in humans across Europe and Asia and is a growing public health concern in Europe and other parts of the world³. FSME-IMMUN/TicoVac is approved in 30 countries and has been

marketed for over 30 years with approximately 120 million doses produced since 1976.

About Pfizer Inc.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

DISCLOSURE NOTICE

The information contained in this release is as of December 1, 2014. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer's acquisition of Baxter's portfolio of marketed vaccines and the potential benefits thereof, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the ability to realize the anticipated benefits of the acquisition; other business effects, including the effects of industry, economic, political or regulatory conditions; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information That May Affect Future Results", as well as in its subsequent reports on Form 10-Q and Form 8-K, all of which are filed with the Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Sources: 1 MMWR 2013; E-CDC report 2008-2009 2 Stein-Zamir 2014; Borg 2009
3 European Centre for Disease Prevent and Control. Epidemiological situation of tick-

borne, encephalitis in the European Union and European Trade Free Association countries, Stockholm: ECDC; 2012

The proposals set forth in this message are subject to compliance with all local legal and regulatory obligations, including the obligation to inform and or consult with labor organizations, works councils, trade unions and employee representatives.

Pfizer Inc. Media: Joan Champion, +1-212-733-2798 Mobile: +1-201-761-9384
Joan.Campion@pfizer.com or Investor: Ryan Crowe, +1-212-733-8160 Mobile: +1-215-260-0914 Ryan.Crowe@pfizer.com